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Background: pneumonia is the leading cause of morbidity and mortality 
among children <5 years of age globally. pneumococcal conjugate vaccines 
(pCVs) are known to provide protection against vaccine serotype pneumococ-
cal pneumonia; uncertainty exists regarding the optimum pCV dosing schedule.
Methods: We conducted a systematic review of studies published from 
1994 to 2010 (supplemented post hoc with studies from 2011) documenting 
the effect of pCV dosing schedules on clinical and radiologically confirmed 
pneumonia, pneumococcal pneumonia and empyema among children of 
ages targeted to receive vaccine. Data on 2- and 3-dose schedules were 
included. percent change of pneumonia incidence rates from baseline to 
most recent year post-pCV introduction was calculated.
Results: We identified 42 primary citations that evaluated pCV schedules 
and pneumonia. thirty-seven (88%) were from north America, europe 
or Australia; 37 (88%) evaluated pCV7 and 1 (2%) pCV10. two studies 
(both observational) compared multiple schedules within the study. We 
found evidence of reduced clinical and radiologically confirmed pneumonia 
incidence for all schedules, including 2+1 (1 nonrandomized trial, 5 obser-
vational studies), 3+0 (5 randomized trials, 2 observational studies) and 
3+1 (5 clinical trials, 24 observational studies) schedules. the magnitude 
of disease impact did not differ among schedules. evidence for impact on 
pneumococcal pneumonia and empyema varied.
Conclusions: All schedules (2+1, 3+0 and 3+1) reduced clinical and radio-
logically confirmed pneumonia. Quantifying differences in pneumonia dis-
ease impact between schedules was difficult due to heterogeneity among 
studies in design, case definition and population. these findings support 
World Health Organization recommendations for 3-dose schedules admin-
istered as either 3+0 or 2+1 regimens. pneumonia impact data are still 
needed on expanded serotype pCV products, developing country settings 
and the role for a booster dose.
Key Words: pneumococcal conjugate vaccine, immunization schedule, 
pneumonia, systematic review
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Globally, pneumonia caused by the bacterium, Streptococcus pneumoniae, is one of the leading causes of nonneonatal 
death in children <5 years of age and is estimated to cause over 
500,000 deaths and nearly 14 million episodes of disease annu-
ally.1,2 Fortunately, pneumococcal conjugate vaccines (pCVs) hold 
promise for preventing much of this burden and are one of the key 
interventions recommended by the Global Action plan for preven-
tion and Control of pneumonia as a means for rapidly reducing 
pneumonia deaths.3–5
three pCV formulations, 7-valent (pCV7), 10-valent 
(pCV10) and 13-valent (pCV13), have been licensed and made 
commercially available. pCV7 was first licensed in 2000 using 
a 4-dose schedule (3 primary doses plus 1 booster, 3+1) and was 
shown to protect against the 7 vaccine serotypes that accounted 
for a significant fraction of pneumococcal disease globally.6 Since 
2010, pCV10 and pCV13 have also been licensed using a 4-dose 
schedule, although all formulations have been granted licensure in 
the european union and elsewhere for schedules using 2 primary 
doses plus 1 booster (2+1) when used as part of a national immu-
nization program.7–9 In addition, the World Health Organization 
has recommended pCV for use on a schedule of 3 primary doses 
without a booster, a typical expanded program on Immunization 
schedule used in many developing countries.4 the exact timing of 
recommended doses varies by country because more policy mak-
ers have added pCV to existing immunization schedules.
Recently, GAVI Alliance support has led to a rapid increase 
in the introduction of pCV into national immunization programs 
among developing countries.10 these introductions, coupled with 
varying national schedules for administering pCV, have prompted 
questions about which infant dosing schedule maximizes the impact 
of pCV programs. to aid in policy development, we conducted a 
comprehensive, systematic review of pCV dosing schedules and 
their impact on pneumonia.
METHODS
Literature Search
this analysis is part of a larger project describing the 
impact of pCV dosing schedules on invasive pneumococcal 
disease (IpD), immunogenicity, nasopharyngeal carriage, pneu-
monia and indirect effects.11–14 Details on the literature search 
terms and methods used in this systematic review are described 
elsewhere (see methods Appendix15). In brief, a systematic 
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literature review was performed to collect all available english 
language data published from January 1994 to September 2010 
(supplemented post hoc with studies from 2011) on the effect of 
various pCV vaccination schedules among immunized children 
on immunogenicity, nasopharyngeal colonization, IpD, pneu-
monia and on indirect effects among unvaccinated populations. 
Articles published in 14 databases, from ad hoc unpublished 
sources and abstracts from meetings of the International Sympo-
sium on pneumococci and pneumococcal Disease (1998–2010) 
and the Interscience Conference on Antimicrobial Agents and 
Chemotherapeutics (1994–2010), were searched. We included all 
randomized controlled clinical trials (RCts), nonrandomized tri-
als, surveillance database analyses and observational studies of 
any pCV schedule on one or more outcomes of interest. Studies 
were included for abstraction if pneumococcal polysaccharide 
vaccine (ppV23) was used as a booster dose, but not as a primary 
dose. titles and abstracts were reviewed twice and those with rel-
evant content on 1 of the 5 outcomes (immunogenicity, carriage, 
invasive disease, pneumonia and indirect effects) underwent full 
review using a standardized data collection instrument. We did 
not search non-english language literature because of the low 
likelihood they would have relevant data for this project. Details 
on the search methods are provided in the methods Appendix.15
Data Abstraction
Citations recovered through the literature search went 
through several stages of independent review to determine their 
eligibility, as described (see methods Appendix15). Citations 
meeting inclusion criteria were categorized on an outcome-
specific basis into “study families,” where each family included 
abstracts or publications generated from a single protocol, popu-
lation, surveillance system or other data collection system rel-
evant to that outcome. Investigators identified primary data from 
the individual studies making up each study family for inclusion 
in the analysis. the primary data were selected as the most current 
and complete data available for that study family. In some cases, 
these data were drawn from >1 publication within a family. We 
also defined “study arms” as a group of children distinguished by 
immunization schedule or pCV product.
We abstracted core information on the following: num-
ber of children in a “study arm;” pCV manufacturer, valency 
and conjugate protein; co-administered vaccines; country; age 
at each dose and date of study and publication. Additional data 
abstracted for pneumonia included specific endpoints, case defi-
nitions, study design, study population and incidence rates or 
percent change.
this article presents the data on the direct effects of pCV 
on pneumonia in children of an age targeted for vaccination. As 
studies included a variety of case definitions for endpoints, findings 
were grouped by endpoint according to the following categories: 
clinical pneumonia (including lower respiratory tract infections and 
acute respiratory tract infections), radiologically confirmed pneu-
monia, pneumococcal pneumonia (including bacteremic pneumo-
nia) and empyema.
Inclusion and Exclusion Criteria
We included data published during or after 1994 from clin-
ical trials, surveillance database analyses and observational stud-
ies of pCV schedules on immunogenicity, IpD,  nasopharyngeal 
carriage, pneumonia and indirect effects. We included all 
licensed and unlicensed pCV products (denoted as pCV with a 
number indicating the valency, eg, pCV7). We excluded studies 
with vaccination series beginning after 12 months of life, as well 
as observational studies that only reported data before or after 
pCV introduction but not for both periods. unless ≥50% vacci-
nation coverage was documented, observational studies were also 
excluded if vaccination was only available through the private 
sector or to high-risk groups. Studies that only provided inci-
dence rates during the year of vaccine introduction, or did not 
specify a period, were excluded.
Pneumococcal Vaccine Dosing Schedules
We defined a primary series as either 2 or 3 doses received 
before 7 months of age. A booster dose was defined as a dose of 
pCV or ppV23 received after 9 months of age and after the com-
pletion of a primary series. A complete series was defined as the 
primary series plus any booster doses implemented in a population; 
examples of this include a 2-dose primary series with or without 
a booster (2+1, 2+0) or a 3-dose primary series with or without a 
booster (3+1, 3+0).
Data Analysis
Studies evaluating impact on pneumonia following pCV 
introduction used a variety of methods; the variety prevented us 
from performing a formal meta-analysis. therefore, we conducted 
descriptive analyses of the amount and variability of the data and of 
the magnitude of the change in the pneumonia outcomes observed 
for each dosing schedule type. We also performed subanalyses to 
evaluate various endpoints related to pneumonia. Studies report-
ing only qualitative data with no ability to determine magnitude of 
impact were excluded from analysis.
For observational studies reporting pneumonia incidence 
over time, we calculated percent change as: (baseline incidence 
—post-pCV introduction incidence)/baseline incidence. Baseline 
incidence was defined as the mean of all data points reported before 
pCV introduction. When annual data on postintroduction incidence 
were available, we calculated percent change using the data point 
given for each year reported. When only the average postintroduc-
tion incidence rate over a period of years was provided, we calcu-
lated percent change from baseline to the reported rate and assigned 
it to the median year of the date range provided. When possible, 
incidence rates during the year of introduction were excluded from 
these calculations. We conducted all analyses using SAS 9.3 (SAS 
Institute Inc., Cary, nC).
RESULTS
Descriptive Characteristics of Included Studies
Of 12,980 citations reviewed, we identified 106 pneumo-
nia outcome citations that met initial criteria for further evalua-
tion (Fig. 1). After further review, 81 citations met inclusion cri-
teria for full data abstraction; of these, 39 studies were excluded 
from analysis because they contained duplicate data of included 
studies or reported changes in pneumonia risk only qualitatively 
so magnitude of impact could not be assessed. Of the 42 included 
citations, 20 evaluated clinical pneumonia, 13 radiologically 
confirmed pneumonia, 16 pneumococcal pneumonia and 9 all-
cause empyema; however, case definitions varied widely for each 
endpoint.16–57
Almost all (n = 39, 93%) citations of pneumonia were pub-
lished during or after 2004. most citations were from north Amer-
ica (n = 23, 55%), europe (n = 9, 22%) or Oceania (n = 5, 12%), 
with the remaining 5 from Africa (n = 3, 7%), Asia (n = 1, 2%) 
and latin America (n = 1, 2%). Although many studies focused on 
the general population of children, 6 citations focused on high-risk 
groups (ie, children with HIV or indigenous populations). thirty-
seven citations evaluated pCV7 and only one study evaluated 
pCV1057 (table 1).
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Studies Directly Comparing Dosing Schedules 
(n = 2 Studies)
We identified only 2 studies, both observational, that com-
pared the effectiveness of different pCV dosing schedules within 
the study itself. One study directly evaluated the impact of 2 ver-
sus 3 primary pCV doses against clinical pneumonia incidence in 
a general pediatric population.28 this propensity-score-matched, 
case-cohort study conducted in the united States evaluated the 
rate of hospitalizations and ambulatory visits for lower respira-
tory tract infections and found that children who received 3 pri-
mary pCV doses had fewer ambulatory visits and hospitaliza-
tions up to the point of receipt of a booster dose (9.5 admissions 
per 1000 children) than those who only received 2 primary doses 
[17.3 admissions per 1000 children; rate difference = 7.8 cases 
per 1000 children (95% confidence interval (CI): 0.8–14.8)]. this 
difference disappeared after the booster dose was administered 
[23.2 admissions per 1000 children vs. 20.9 admissions per 1000 
children for 3+1 vs. 2+1, respectively; rate difference = −2.3 
cases per 1000 children (95% CI: −14.8 to 9.3)]. this differ-
ence between 2 and 3 primary doses was seen for children born 
in the 2002 birth cohort, but not for children born in 2003; the 
authors hypothesized that by 2003, 3 years after introduction 
of pCV7, herd effects had lessened the difference in risk between 
the 2 groups. the other study directly comparing dosing sched-
ules, a retrospective cohort conducted among Australian Indig-
enous infants,53 evaluated risk of clinical and radiologically con-
firmed pneumonia after each of 3 pCV7 primary doses plus 1 
ppV23 booster (3+ppV23) but did not find evidence of reduced 
risk for either endpoint by number of doses.
Studies of Single Schedules
Two-dose Primary Schedules, With a Booster, in the 
 General Population (n = 6 Studies)
Of studies assessing a single schedule, none evaluated the 
impact of 2 primary doses on pneumonia in the first year of life 
(ie, up to the point of receiving the booster dose) or in the second 
year of life without a booster dose (2+0). We identified 6 studies 
(6  citations) that evaluated the impact of a 2+1 schedule on 
pneumonia: one  prospective cohort trial35 and 5 observational 
 studies.16,30,34,50,54 the cohort study was a nonrandomized, single-
blinded Italian study that found an impact of pCV7 on radio-
logically confirmed pneumonia (vaccine efficacy: 65%, 95% 
CI: 47–78%; table 2). parents participating in the study could 
choose whether to have their children vaccinated, and providers and 
106 Citations in original search  
(88 original and 18 updates) 
14 Reviews 
7 No pneumonia 
outcome 
Other exclusions: 
2 PPV23 only 
1 post PCV data only 
1 age ineligible group 
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FIGURE 1. Flowchart of included citations.
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parents were not blinded to the intervention; these design limita-
tions may explain why the point estimate is higher than that seen in 
blinded RCts of pneumonia.
Of the 5 observational studies, 3 reported data on clinical 
pneumonia, 2 on radiologically confirmed pneumonia, 2 on pneu-
mococcal pneumonia and 2 on empyema (table 3). All studies eval-
uating the effectiveness of 2+1 pCV against clinical and radiologi-
cally confirmed pneumonia showed evidence of significant disease 
reduction after pCV introduction into the national immunization 
program. Results of the limited number of studies on pneumococ-
cal pneumonia and empyema were mixed (table 3). Of the 2 studies 
on pneumococcal pneumonia following 2+1 pCV dosing, 1 from 
Italy found a significant decline in hospitalizations for pneumococ-
cal pneumonia after pCV introduction,30 while the other from Bel-
gium found no significant decrease in incidence of pneumococcal 
pneumonia in children <2 years of age and a significant increase in 
incidence in children 2–4 years of age.16 Of the two 2+1 studies on 
empyema, one found a 22% decline in empyema,50 while the other 
found no significant change in empyema rates following pCV intro-
duction into the national immunization program.34
Three-dose Primary Schedules, With or Without Booster, 
in the General Population (n = 28 Studies)
Of studies assessing a single schedule, 5 (6 citations) evalu-
ated a 3+0 schedule and 23 (24 citations) evaluated a 3+1 sched-
ule on various pneumonia disease endpoints. Of the 3+0 schedule 
studies, we identified 3 RCts22,23,25,26 from various regions (table 2) 
and 2 observational studies, both from Australia45,49 (table 4). each 
of the RCts showed efficacy against clinical or radiologically 
confirmed pneumonia; the clinical trial in the philippines showed 
impact of pCV11 (Sanofi pasteur, lyon, France) on radiologically 
confirmed pneumonia but not clinical pneumonia.25 Both observa-
tional studies showed significant reductions in disease burden fol-
lowing pCV introduction into the Australian national immunization 
program, with reductions ranging from 28% to 38% for clinical 
pneumonia and from 45% to 77% for pneumococcal pneumonia 
depending on the age group (table 4).
We identified 3 clinical trials29,31,38,57 and 20 observational 
studies that evaluated the impact of a 3+1 schedule on pneumonia end-
points (8 on clinical pneumonia,19,21,27,36,37,43,48,51 4 on radiologically 
confirmed pneumonia,40,43,52,55 7 on empyema24,32,33,39,44,48,51 and 12 
on pneumococcal pneumonia17,19,21,33,37,41,42,44,46–48,51) (tables 2 and 5). 
All clinical trials and observational studies showed evidence of 
pCV benefit on clinical and radiologically confirmed pneumonia; 
however, 1 German study was a nonrandomized, single-blinded 
clinical trial, which limits interpretation of their findings,29 and 
in some observational studies, the results did not reach statistical 
significance36,43 or found significant reductions only in children 
<2 years of age19,37,48 (tables 2 and 5). Of the 7 observational stud-
ies that evaluated a 3+1 schedule on all-cause empyema, 5 found 
a significant increase in empyema rates after pCV introduction, 
with many attributing these increases to pneumococcal serotypes 
TABLE 1. Characteristics of Citations Included in Analysis
Characteristic
Complete Dosing Schedule*
Total† 2+1 3 + 0 3 + 1‡
n = 42 (%) n = 6 (%) n = 7 (%) n = 29 (%)
Year of publication
  1994–1998 1 (2) 0 0 1 (3)
  1999–2002 2 (5) 0 0 2 (7)
  2003–2006 12 (29) 0 3 (43) 9 (31)
  2007–2011 27 (64) 6 (100) 4 (57) 17 (59)
Study type
  Clinical trial 11 (26) 1 (17) 5 (71) 5 (17)
  Observational 31 (74) 5 (83) 2 (29) 24 (83)
  Case-control 0 0 0 0
Region
  Africa 3 (7) 0 3 (43) 0
  Asia 1 (2) 0 1 (14) 0
  Australia/Oceania 5 (12) 0 3 (43) 2 (7)
  Europe 9 (22) 5 (83) 0 4 (14)
  Latin America 1 (2) 0 0 1 (3)
  North America 23 (55) 1 (17) 0 22 (76)
PCV product
  PCV7 37 (88) 6 (100) 3 (43) 28 (97)
  PCV9 3 (7) 0 3 (43) 0
  PCV10 1 (2) 0 0 1 (3)
  PCV11 1 (2) 0 1 (14) 0
  PCV13 0 0 0 0
High-risk population
  HIV 2 (5) 0 2 (29) 0
  Indigenous 3 (7) 0 0 3 (10)
  Neonates 1 (2) 0 1 (14) 0
Endpoint
  Clinical pneumonia (including lower 
respiratory tract  infections) 20 (47) 3 (50) 5 (71) 12 (39)
  Radiologically confirmed  
pneumonia 13 (30) 3 (50) 3 (43) 7 (23)
  Pneumococcal pneumonia 16 (37) 2 (33)  2 (29) 12 (39)
  Empyema 9 (21) 2 (33) 0 7 (23)
*There were no citations that evaluated a 2+0 schedule.
†Numbers are not mutually exclusive as some citations presented findings on multiple characteristics.
‡3+1 schedules include 3+PPV23.
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not found in pCV7 or other pathogens such as multi-drug resist-
ant Staphylococcus aureus.32,33,39,48,51 evidence for the impact of a 
3+1 schedule on pneumococcal pneumonia varied (table 5). eight 
studies showed a decrease in pneumococcal pneumonia rates, 5 
with significant findings.17,19,21,37,48 Four studies found an increase, 2 
with significant findings.41,44 Of the 4 studies showing an increase in 
pneumococcal pneumonia rates, 2 were conducted in Spain while 
pCV7 coverage rates were <50%44,47 and 1 was conducted in the 
united States41 that noted a pCV7 shortage limiting vaccine avail-
ability. two of the 4 studies with increases in pneumococcal pneu-
monia rates also documented an increase in invasive disease rates 
due to non-pCV7 serotypes.41,44
PCV Dosing Schedules in High-Risk  
Populations (n = 5 Studies)
Among 5 studies evaluating the impact of pCV on popula-
tions at high risk for pneumococcal disease, 2 (3 citations) used a 
3+0 schedule and 3 used a 3+1 schedule. two RCts evaluated the 
impact of pCV7 among a high-risk population using a 3+0 schedule 
(table 2).18,22,26 One trial, conducted in South Africa, found a 13–15% 
efficacy against clinical and radiologically confirmed pneumonia in 
children with HIV. the other clinical trial, from papua new Guinea, 
found pCV7 to be 18% (95% CI: 4–31%) efficacious against clini-
cal pneumonia in neonates.18 We identified 1 RCt56 and 2 observa-
tional studies20,52 from the united States and Australia that evaluated 
a 3+1 (3+ppV23 for Australian Indigenous) schedule in indigenous 
populations. the RCt, conducted among a population of American 
Indians in the united States, showed no efficacy against the first 
episode of radiologically confirmed pneumonia (authors' data, per 
protocol vaccine efficacy: –8.0%, 95% CI: –37.0% to 14.9%); how-
ever, only inpatient pneumonia cases were included in this analysis 
unlike other RCts. One of the observational studies found a trend of 
declining incidence for clinical pneumonia in Australian Indigenous 
children; however, this finding was not significant (P = 0.13), and 
study investigators speculate the lack of sufficient follow-up time as 
a possible reason.52 the other observational study, evaluating empy-
ema in a uS Alaskan native pediatric population, found no change 
in empyema-associated hospitalizations following pCV introduc-
tion and rates remained higher than those for children in the general 
uS population.20 Study investigators did note an apparent increased 
rate in empyema due to S. pneumoniae and, in particular, episodes 
due to nonvaccine serotypes, which could explain the lack of change 
in overall empyema rates.
DISCUSSION
this analysis found strong evidence of pCV benefit against 
both clinical and radiologically confirmed pneumonia in the age 
group targeted for vaccination using 2+1, 3+0 and 3+1 schedules. 
Data from several RCts, including trials in low-income settings, 
strongly support use of 3 primary dose schedules with or without 
a booster (ie, 3+0 or 3+1) for prevention of pneumonia. A large 
number of observational studies support use of either 3 primary 
doses, with or without a booster, or 2 primary doses plus 1 booster 
(2+1), which demonstrates the benefits of these schedules for pneu-
monia prevention in a routine immunization setting. Overall, half 
(21 of 42) of the studies in our review provided evidence for sig-
nificant reductions in 1 or more disease endpoints. the evidence 
for 1 schedule over another and the impact of pCV in preventing 
pneumococcal pneumonia and empyema were less clear, given the 
small number of studies and their conflicting findings.
Immunization with pCV is critical to provide protection 
against pneumonia in the first year of life. However, quantifying the 
differences in benefit between 2-dose and 3-dose primary immuni-
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directly compared different schedules within the same study. pelton 
et al.28 directly compared 2 versus 3 primary doses in an observa-
tional study of an immature immunization program and found that 
3 primary doses were superior to 2 doses in preventing hospitaliza-
tions for clinical pneumonia before a booster dose, but only early 
in the vaccination program (presumably before the indirect effect 
matured). the other study, conducted among Australian Indigenous 
infants, also found that 3 primary doses were superior to 2 doses, 
but under the condition of almost no effect from receipt of 3 pri-
mary doses compared with receipt of 0 doses in preventing clinical 
pneumonia and an increased risk with receipt of 2 primary doses.53 
Study investigators speculated that replacement of vaccine sero-
types with either nonvaccine serotypes or other respiratory patho-
gens carried in the nasopharynx may have increased clinical pneu-
monias among infants. the remaining studies evaluating a single 
schedule compared with no vaccination showed evidence of impact 
on pneumonia burden using 2+1, 3+0 or 3+1 schedules; there were 
no discernible differences in the magnitude of that impact accord-
ing to a specific dosing schedule. Findings from individual stud-
ies were not comparable with each other as the measured impact 
was dependent on a variety of study methods, case definitions and 
populations, which, due to the heterogeneity of the data, we were 
unable to control for in analysis. Despite this limitation, our find-
ings support the use of pCV in effectively reducing disease burden 
and complement a recent systematic review that evaluated the sub-
set of pCV studies making direct schedule comparisons; because of 
limited or no data meeting inclusion criteria, that review was unable 
to assess clinical outcomes regarding pneumonia.58
In addition to the heterogeneity of study designs evaluating 
different pCV schedules, the nonspecificity of pneumonia endpoints 
and myriad case definitions complicated the ability to adequately 
summarize and interpret findings regarding impact of pCV sched-
ules on pneumonia. Studies using more narrow and specific end-
points and case definitions, such as World Health Organization 
(WHO)–standardized definitions, likely provide a more accurate 
picture of pCV impact on disease specifically caused by pneumo-
coccus. Studies that use a more generic endpoint, such as clinical 
pneumonia, are more prone to include cases caused by pathogens 
other than pneumococcus and mask any true impact. A few stud-
ies have assessed the impact of specificity of disease endpoints by 
retrospectively applying more specific case definitions and re-eval-
uating pCV impact. In each case, a higher efficacy was measured 
with increased specificity for the disease endpoint.26,38,59,60 However, 
capturing cases with a more specific case definition is not always 
appropriate or feasible given limited resources (ie, access to labora-
tory or clinical diagnostics, population access to care, limited sur-
veillance area) and confounding factors (ie, high burden of underly-
ing conditions such as malaria or HIV) in many studies evaluating 
implementation in routine settings. We found evidence of this in our 
review of case definitions; the most rigorous and specific case defi-
nitions were more often used in the setting of controlled trials while 
observational studies were more likely to use nonspecific case defi-
nitions. Case definitions ranged in specificity and inclusion criteria 
with some studies using International Classification of Diseases, 
9th edition (ICD-9) or International Classification of Diseases, 10th 
edition (ICD-10) administrative database codes or clinician diagno-
sis, while others used WHO-standardized definitions or laboratory 
confirmation. this lack of specificity and standardization within 
case definitions may explain some of the variability in findings and 
the inability to interpret reductions in certain disease endpoints. 
nevertheless, our review found sufficient evidence of pCV impact 
against pneumonia outcomes: 12/20 (60%) studies found significant 
reductions in clinical pneumonia, 6/11 (55%) radiologically con-
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essential for future studies to consider more pneumococcal-specific 
and standardized case definitions to accurately and consistently 
measure the impact of pCV against pneumonia.
the studies included in this analysis represent a number of dif-
ferent settings and populations, which, while providing a breadth of 
data, also made it difficult to discern differences between schedules. 
many data collected from settings of routine immunization focused 
on pCV7 and were from low disease burden, higher income countries, 
complicating the ability to extrapolate findings to other pCV products 
and to low- and middle-income countries, which often have higher 
rates of disease burden and more constrained resources. In addition, 
many populations in lower income countries have higher rates of 
underlying health conditions (eg, HIV or sickle cell disease) that can 
increase risk of developing pneumonia. We found only 6 studies that 
evaluated the impact of pCV in populations at higher risk for disease 
and magnitude of disease reduction varied greatly. Despite this limita-
tion in geographical representation in settings of routine immuniza-
tion, all RCts evaluating 3+0 schedules were from low-income or 
lower-middle income countries and showed impact of pCV in these 
populations. As a greater number of countries have now introduced 
pCV into national immunization programs, ongoing studies in lower 
income settings and studies using various pCV products (pCV10 or 
pCV13) will contribute to additional evidence of impact.61,62
Our review of the literature on impact of pCV dosing sched-
ules found evidence of impact on varying pneumonia endpoints 
using 2+1, 3+0 and 3+1 schedules, although the preponderance of 
evidence informed 3+1 schedules, with fewer data available regard-
ing 2+1 and 3+0 schedules. Our findings support recommendations 
by the pan American Health Organization and WHO for using a 
3-dose regimen, which can be given as either 3+0 or 2+1, and given 
a lack of evidence supporting 2+0 schedules, choosing a schedule 
that ensures high coverage with a third dose is essential.63,64 Further-
more, due to current data limitations and heterogeneity of the data, 
the optimal schedule in a given epidemiological setting for those 3 
doses is dependent on a range of disease impact and programmatic 
considerations. As more countries make a decision to introduce 
pCV into national immunization programs, it will be essential for 
policy makers to consider programmatic and epidemiologic factors 
when making decisions regarding the ideal dosing schedule for their 
program. to ensure stakeholders are well-informed, more data are 
needed to evaluate pCV10 and pCV13 and the impact of these vac-
cines on pneumonia in developing countries. For all such studies, use 
of specific, standardized case definitions and evaluations that include 
direct schedule comparisons will greatly enhance the strength of evi-
dence on which to formulate optimal dosing policies and achieve the 
greatest disease reductions for the doses administered.
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